Gracell Biotechnologies Inc. (GRCL) Company Revenue

High utilization of automated sterile laboratories provides a stable production base for Gracell Biotechnologies (GRCL). The company's commercial revenue trend on the current GURU.Markets platform chart reflects dynamics where 0.00 is the current value of the indicator. Growth is supported by strategic R&D partnerships with clinics, while business success depends on the safety of genetic modifications and the precision of CAR-T therapy clinical trials.

GRCL - Gracell Company Sales over the range 07/04/2022 - 03/03/2024

Comprehensive metric breakdowns and analytics for gracellbio.com (GRCL)

- market price and analyst price targets:

Market Price gracellbio.com|GRCL - Price Target Chart

- market capitalization details:

Market Value Gracell Biotechnologies Ltd|GRCL - Total Company Value

- book capitalization information:

Net Assets per Single Share Gracell Biotechnologies|GRCL - Company Net Assets|Market Value to Book Value gracellbio.com|GRCL - Company Total Assets

- company liabilities and liquidity data:

- earnings and market ratios statistics:

GRCL - Net Income|Future Net Profit Gracell Biotechnologies|GRCL - P/E Multiple|Future Price to Earnings Multiple Gracell Biotechnologies Inc.|GRCL - PEG Multiple|Company Value to EBITDA Gracell Biotechnologies Ltd|GRCL - Profit before payment of interest, taxes and amortization|Earnings per share for the trailing year Gracell Biotechnologies|GRCL - Net earnings per share (EPS TTM)|Quarterly EPS earnings growth gracellbio.com|GRCL - Earnings per share growth in current year|Net earnings per share change forecast for next year Gracell Biotechnologies

- issuer revenue and sales details:

GRCL - Company Sales|Company Expected Sales Volume Gracell Biotechnologies|GRCL - P/S Multiple|Projected Price to Revenue Gracell Biotechnologies Ltd

Comprehensive company analysis:Gracell Biotechnologies GRCL

Mass-produced product of Gracell Biotechnologies

A fundamental valuation of Gracell Biotechnologies (GRCL) requires a cash flow analysis to understand the sustainability of T-cell therapy development in China and the US. The daily volume of actual inflows reflected in the company's sales profile allows for the identification of business overheating risks by comparing current revenue with historical cycles to forecast a potential decline in the efficiency of the scientific portfolio within onco-hematology treatment.

Key competitors